New biotech startup targets genes to treat skin diseases
A new biotech startup developing immuno-dermatology technologies for skin diseases has launched today with $100mn (€93mn) in seed funding. Based in Boston and Geneva, Alys Pharmaceuticals is co-founded by Medicixi, a European healthcare-focused investment firm, and six university scientists, including...
